Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
ONC206
As low as
180
CHF
CHF 180.00
In stock
Only %1 left
CDX-O0206-M02525 mgCHF 180.00
NEW
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | ONC-206; 7-Benzyl-4-(2,4-difluorobenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one; NSC783746 |
| Product Type | Chemical |
| Properties | |
| Formula | C23H22F2N4O |
| MW | 408.44 |
| CAS | 1638178-87-6 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥99% (HPLC) |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or methanol. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | ITMGVSSHWMTJRR-UHFFFAOYSA-N |
| Smiles | O=C1C2=C(CCN(C2)CC3=CC=CC=C3)N4C(N1CC5=CC=C(C=C5F)F)=NCC4 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Scientific Background Information
Product Description
ONC206 is a second-generation imipridone widely used in cancer and mitochondrial biology research. It acts as a potent agonist of the mitochondrial caseinolytic protease P (ClpP), leading to disruption of mitochondrial proteostasis, impairment of oxidative phosphorylation and induction of metabolic stress in tumor cells. ONC206 has demonstrated potent antitumor activity in a variety of preclinical cancer models and is employed to investigate mitochondrial metabolism, apoptosis, integrated stress response signaling and the therapeutic potential of ClpP activation in oncology. It has also been described as a low-potency dopamine receptor D2 (DRD2) antagonist.
Product-specific References
(1) J.L. Carter, et al.; Biochem. Pharmacol. 182, 114253 (2020) | (2) Y. Zhang, et al.; Front. Oncol. 10, 577141 (2020) | (3) A. Staley, et al.; Am. J. Cancer Res. 11, 5374 (2021) | (4) K. Tucker, et al.; Am. J. Cancer Res. 12, 521 (2022) | (5) T.T.T. Nguyen, et al.; Clin. Cancer Res. 28, 1881 (2022) | (6) J. Cao, et al.; Neoplasia. 55, 101015 (2024) | (7) A. Monzer, et al.; Pharmacol. Rep. 77, 229 (2025) | (8) R. Agren & K. Sahlholm; Neurooncol. Adv. 7, vdaf185 (2025)